Safety and acceptability of exercise for chronic lymphocytic leukaemia

Not Applicable

• Conditions: Chronic lymphocytic leukaemia; Cancer; Chronic lymphocytic leukaemia of B-cell type

• Registration Number: ISRCTN55166064
• Lead Sponsor: niversity of Bath

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-23
• Last Update Posted: 4 October 2021
• Study Completion: 2023-03-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Males and females with a diagnosis of chronic lymphocytic leukaemia, defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines as the presence of 5000 B cells per µL of peripheral blood, sustained for at least 3 months and confirmed by the blood smear, immunophenotype and in some cases genetic features of lymphoid cells (Hallek et al., 2018a)
2. Age >18 years old
3. Asymptomatic early-stage disease monitored without anti-CLL treatment
4. Physically inactive (defined by World Health Organisation as ‘an insufficient physical activity level to meet present physical activity recommendations’. Current physical activity guidelines for adults are at least 150-300 minutes of moderate-intensity aerobic physical activity, or at least 75-150 minutes of vigorous-intensity aerobic physical activity, or an equivalent combination of both throughout the week (Bull et al., 2020))
5. Access to an appropriate electronic device (e.g. laptop, tablet or smartphone) with an appropriate wireless internet connection (and data allowance if relevant) capable of streaming video
6. All participants will have completed the full appropriate vaccination schedule including seasonal influenza, pneumococcal and COVID-19

Exclusion Criteria

1. World Health Organisation (WHO)/ Eastern Cooperative Oncology Group (ECOG) performance status >1
2. Pregnancy
3. Deemed unsafe to exercise according to the Physical Activity Readiness Questionnaire (PARQ)
4. Any comorbidity that is likely to progress or be exacerbated over the course of the trial period (e.g. history of syncopal events, significant cardiac or respiratory events)
5. Cognitive impairment deemed a risk by the healthcare team for participation in the trial (e.g. diagnosis of neurodegenerative disease)
6. Unable to understand explanations and/or provide informed consent
7. Any condition and/or behaviour that would pose an undue personal risk or introduce bias into the trial
8. Recent blood counts at levels that are deemed to pose an undue risk by the healthcare team

Study & Design

• Study Type: Interventional
• Study Design: Not specified